Engineering regenerative cell therapy products through biofabrication.

Authors

Ponpaphas Niltongkam, Xinrong Song, Yuhan Liu, Jingqi Hu, Zhuo Xiong, Yongcong Fang

Published in

Trends in biotechnology. Nov 10, 2026. Epub Nov 10, 2026.

Abstract

Regenerative cell therapies delivered as cell suspensions often face limited survival, retention, and tissue integration. Biofabrication produces structured living products with controlled cellular organization and material environments. Here, we present a product-oriented framework linking fabrication-derived attributes to therapeutic function, delivery compatibility, manufacturing reproducibility, quality control, and safety and regulatory evidence. We distinguish biomaterial-free and biomaterial-based products based on whether exogenous biomaterials are retained as structural or functional components of the administered construct, and examine hybridization as an integration strategy. Comparisons across formats assess whether engineered features provide therapeutic value sufficient to justify added manufacturing and translational burdens. This framework guides product design toward the minimum complexity needed to achieve clinically meaningful function with reproducible manufacture and delivery.

PMID:
43009409
Bibliographic data and abstract were imported from PubMed on 11 Nov 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.